JP2022531939A - がんを処置する方法 - Google Patents

がんを処置する方法 Download PDF

Info

Publication number
JP2022531939A
JP2022531939A JP2021566481A JP2021566481A JP2022531939A JP 2022531939 A JP2022531939 A JP 2022531939A JP 2021566481 A JP2021566481 A JP 2021566481A JP 2021566481 A JP2021566481 A JP 2021566481A JP 2022531939 A JP2022531939 A JP 2022531939A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cancer
acceptable salt
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531939A5 (cg-RX-API-DMAC7.html
Inventor
ギャビン ベネット,
ギリアン ラングフォード,
ピーター パーク,
ジョハンナ ラーデンランタ,
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022531939A publication Critical patent/JP2022531939A/ja
Publication of JP2022531939A5 publication Critical patent/JP2022531939A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021566481A 2019-05-10 2020-05-11 がんを処置する方法 Pending JP2022531939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846064P 2019-05-10 2019-05-10
US62/846,064 2019-05-10
PCT/GB2020/051140 WO2020229803A1 (en) 2019-05-10 2020-05-11 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2022531939A true JP2022531939A (ja) 2022-07-12
JP2022531939A5 JP2022531939A5 (cg-RX-API-DMAC7.html) 2023-05-18

Family

ID=70847425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566481A Pending JP2022531939A (ja) 2019-05-10 2020-05-11 がんを処置する方法

Country Status (10)

Country Link
US (3) US11414488B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965757A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531939A (cg-RX-API-DMAC7.html)
CN (1) CN113993537A (cg-RX-API-DMAC7.html)
AU (1) AU2020273615A1 (cg-RX-API-DMAC7.html)
CA (1) CA3139035A1 (cg-RX-API-DMAC7.html)
IL (1) IL287907A (cg-RX-API-DMAC7.html)
SG (1) SG11202112452WA (cg-RX-API-DMAC7.html)
TW (1) TWI869398B (cg-RX-API-DMAC7.html)
WO (1) WO2020229803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
WO2018096365A1 (en) * 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP2019501224A (ja) * 2016-01-08 2019-01-17 ユークリセス ファーマシューティカルズ,インコーポレイテッド クロメン化合物および第2活性薬剤の併用薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
SI4339615T1 (sl) * 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
MX2019007367A (es) 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CA3116504A1 (en) 2018-10-30 2020-05-07 Bicyclerd Limited Bt1718 for use in treating cancer
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
EP4045075A1 (en) 2019-10-16 2022-08-24 Bicyclerd Limited Methods for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
JP2019501224A (ja) * 2016-01-08 2019-01-17 ユークリセス ファーマシューティカルズ,インコーポレイテッド クロメン化合物および第2活性薬剤の併用薬
WO2018096365A1 (en) * 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHARM. RES., vol. 34, JPN6024014674, 2017, pages 629 - 639, ISSN: 0005309642 *
THE CANCER JOURNAL, vol. Vol.23(1), JPN6024014675, 2017, pages 10 - 22, ISSN: 0005519375 *
THE FASEB JOURNAL, vol. 22, JPN6024014676, 2007, pages 659 - 661, ISSN: 0005519374 *

Also Published As

Publication number Publication date
US20240199742A1 (en) 2024-06-20
TWI869398B (zh) 2025-01-11
US20230025971A1 (en) 2023-01-26
WO2020229803A1 (en) 2020-11-19
US20200354456A1 (en) 2020-11-12
CA3139035A1 (en) 2020-11-19
IL287907A (en) 2022-01-01
US11414488B2 (en) 2022-08-16
SG11202112452WA (en) 2021-12-30
EP3965757A1 (en) 2022-03-16
AU2020273615A1 (en) 2021-12-02
CN113993537A (zh) 2022-01-28
TW202108165A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
TWI869398B (zh) 治療癌症之方法
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
JP2020525427A (ja) 癌を処置するための方法
JP2020520921A (ja) 癌を処置する併用療法
CA2879548C (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2023165946A (ja) Ep4阻害剤およびその使用
JP2021530487A (ja) Ep4阻害剤およびその合成
EP4108242B1 (en) Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient
TWI747868B (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
US12295962B2 (en) Polymorphic compounds and uses thereof
US20200399377A1 (en) Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
US20250241913A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
EP3915585A1 (en) Therapeutic combinations comprising agonists of ferroptosis for treating proliferative disorders
WO2023114984A1 (en) Tead inhibitors and uses thereof
JP2022500485A (ja) グラピプラント単位剤形
CN110464845B (zh) 一种用于乳腺癌免疫治疗的联合用药物组合及其应用
SG10202111361TA (en) Treatment of alopecia areata
JP2022529434A (ja) がんの治療に使用するための免疫チェックポイント阻害剤と組み合わせるペプチド
KR20160101027A (ko) 제약 조합물
JP2024515100A (ja) 特定のhdac6阻害剤及び、少なくとも一つのctla4チェクポイント阻害剤を含む組合せ
CA3189061A1 (en) Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients
EA048934B1 (ru) Способы лечения рака
WO2026074499A1 (en) Methods and compositions for inhibiting c-myc
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
JP2016518400A (ja) 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220728

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204